| Literature DB >> 34777621 |
William Liu1, Salida Mirzoeva1, Ye Yuan1, Junjing Deng2, Si Chen3, Barry Lai3, Stefan Vogt3, Karna Shah1, Rahul Shroff1, Reiner Bleher4, Qiaoling Jin2, Nghia Vo5, Remon Bazak6, Carissa Ritner1, Stanley Gutionov1, Sumita Raha1, Julia Sedlmair7, Carol Hirschmugl7,8, Chris Jacobsen2,3, Tatjana Paunesku1, John Kalapurkal1, Gayle E Woloschak1.
Abstract
BACKGROUND: Neuroblastoma is the most common extracranial solid malignancy in childhood which, despite the current progress in radiotherapy and chemotherapy protocols, still has a high mortality rate in high risk tumors. Nanomedicine offers exciting and unexploited opportunities to overcome the shortcomings of conventional medicine. The photocatalytic properties of Fe3O4 core-TiO2 shell nanocomposites and their potential for cell specific targeting suggest that nanoconstructs produced using Fe3O4 core-TiO2 shell nanocomposites could be used to enhance radiation effects in neuroblastoma. In this study, we evaluated bare, metaiodobenzylguanidine (MIBG) and 3,4-Dihydroxyphenylacetic acid (DOPAC) coated Fe3O4@TiO2 as potential radiosensitizers for neuroblastoma in vitro.Entities:
Keywords: Iron oxide core nanoparticles; Nanocomposites; Nanoconjugates; Neuroblastoma; Radiosensitization; Titanium dioxide shell nanoparticles
Year: 2021 PMID: 34777621 PMCID: PMC8550682 DOI: 10.1186/s12645-021-00081-z
Source DB: PubMed Journal: Cancer Nanotechnol ISSN: 1868-6958
Fig. 1Nanocomposite and nanoconjugate Cryo-TEM show different degrees of aggregation resulting in corresponding differences in nanocomposite uptake by neuroblastoma cells. a Cryo-TEM images of bare Fe3O4@TiO2 nanocomposites; b DOPAC–Fe3O4@TiO2 nanoconjugates, and c MIBG–DOPAC–Fe3O4@TiO2 nanoconjugates mixed with complete cell media, plunge-frozen on lacy carbon grids and imaged under cryogenic conditions at 120 kV. For EDS–STEM and IR spectroscopy of nanocomposites, see supplemental Figs. 1 and 2. d SK-N-AS cells were treated with 250 nM bare Fe3O4@TiO2 nanocomposites, DOPAC–Fe3O4@TiO2 nanoconjugates or MIBG–DOPAC–Fe3O4@TiO2 nanoconjugates for 1 h (n = 3), washed and collected after trypsinization. Bar graph shows relative quantity of Ti per 105 cells; e same work was done with SK-N-DZ cells. The total concentration of Ti (ppb) per sample was evaluated by ICP-MS and adjusted for the number of cells counted prior to sample processing for ICP-MS. The final concentration of Ti per 105 cells is expressed as a percentage of bare Fe3O4@TiO2 nanocomposite uptake; control value corresponds to Ti background from cells not treated with nanoconstructs. Data presented are an average of at least two independent experiments, each with three biological replicates. Error bars indicate mean ± SD. *** < 0.001 significance level
Fig. 2Cryo-XFM imaging of SK-N-AS cells treated with three different nanocomposites. a SK-N-AS cells were treated with 250 nM Fe3O4@TiO2 nanocomposites for 1 h. The distribution of Ti and Fe (as proxy for nanocomposites) in SK-N-AS cells was cytoplasmic or associated with the membrane; b the same cell was imaged after a 45 degree rotation, with all Ti signal separated from the Zn-rich area of the nucleus; c SK-N-AS cells treated with DOPAC–Fe3O4@TiO2 nanoconjugates showing large aggregates with dense concentration of Ti and Fe; d SK-N-AS cells also display punctate pattern of smaller aggregates of nanocomposites apparently co-localizing with Mn and Zn signal. e SK-N-AS cells treated with MIBG–Fe3O4@TiO2 nanoconjugates. Some co-localization of Ti and Fe puncta with Mn and Zn is observed, indicating either potential mitochondrial or nuclear distribution of MIBG–Fe3O4@TiO2 nanoconjugates. f After a + 60 degree rotation, image of the lower portion of same cell is still indicating Ti and Mn co-localization for aggregates nc 3 and nc 4; g scan of the upper portion of the same cell after a -60 degree rotation suggests that aggregate nc1 is in fact immediately above the nucleus. Scale bar and elemental concentration indicator (black—no signal to red—highest signal) are located under each image
Fig. 3Tomographic imaging of targeted MIBG–Fe3O4@TiO2–B-loop nanoconjugates by Cryo-XFM indicates partial nuclear localization of the nanoconjugates. a A single XFM projection of a SK-N-AS cell treated with a 60 µM equivalent treatment of MIBG–Fe3O4@TiO2–B-loop nanoconjugates indicates extensive cytoplasmic and nuclear accumulation of nanoconjugates. Scale bar and elemental concentration indicator (black—no signal to red—highest signal) are located under image. Co-localization image: blue: iodine, red: Ti, green: zinc (overlapping color for all three elements is white). b–d Screen captures of different single-angle projections of the tomographic reconstruction of the cell seen in a. Different rotation projections confirm the localization of Ti and Fe in the nucleus. e Rotation projection focused on the iodine signal (indication of MIBG) corresponds to the same locations in the cell nucleus seen in b. f SK-N-DZ cell treated with MIBG–Fe3O4@TiO2–B-loop nanoconjugates, also suggesting nuclear localization of I and Ti
Fig. 4Effect of MIBG nanoconjugates on neuroblastoma cell viability. a SK-N-AS cells; b SK-N-DZ; c NBL-W/S and d NBL-W/N were treated with varying concentrations of Fe3O4@TiO2–MIBG nanoconjugates. Loss of viability was observed by MTS assay as detailed. e HeLa cells treated with 100 nM or 250 nM Fe3O4@TiO2 bare nanocomposites or MIBG nanoconjugates. f SK-N-DZ cells treated with free MIBG (9.3 µM), bare nanocomposites (100 nM), or bare nanocomposites + free MIBG. No decrease in cell viability was found in either treatment condition *: < 0.05 significance level, **: < 0.01 significance level, *** < 0.001 significance level. Datapoints presented are an average of 5 biological replicates. Error bars indicate mean ± SD
Fig. 5Radiosensitizing effects of bare nanocomposites and DOPAC-coated nanoconjugates. a, c SK-N-AS and b, d SK-N-DZ cells were irradiated in the presence of bare (Bare-NCs) or DOPAC-coated (DOPAC-NCs) nanoconstructs of different concentrations. Curves were generated by adjusting cell viabilities to 100% for non-irradiated cells in each nanoconstruct treated group. A statistically significant radiosensitizing effect was observed at 250 nM bare nanocomposites in both cell lines, particularly at 10 Gy. Datapoints presented are average of 5 biological replicates and are representative of at least two independent MTS experiments. Error bars indicate mean ± SD. e Annexin V/propidium iodide flow cytometry assay of SK-N-AS cells 24 h after irradiation (0 or 10 Gy) preceded by treatment with 250 nM DOPAC-nanocomposites. H2O2 was the positive control. Three independent experiments were done, with 3 biological replicates per experiment. Con = cells not exposed to nanoconjugates; NC = DOPAC nanoconjugate treatment; f percentage of SK-N-AS cells with > 20 foci per nucleus, for untreated or treated with 250 nM bare nanocomposites or 250 nM DOPAC-nanoconjugates for one hour and irradiated as indicated. 53BP1 foci were stained by immunocytochemistry while the nuclei were counterstained with propidium iodide (PI). At least 100 cells were counted for each treatment group per replicate. N = total number of biological replicates from 4 independent experiments of 1–2 replicates each. There was a significant increase in the percentage of cells with > 20 foci after 2 Gy treatment. g Representative images of cells shown in f. Error bars indicate mean ± SD. * < 0.05 significance level, ** < 0.01 significance level, *** < 0.001 significance level when treatment sample is compared to untreated and/or unirradiated control
Cell viabilities in the presence of bare nanocomposites following irradiation
| Fe3O4@TiO2 | 0 nM | 100 nM | 250 nM | |
| SK-N-AS | 0 Gy | 100 ± 2.22 | 100 ± 2.00 | 100 ± 1.42 |
| 2 Gy | 88.15 ± 2.85 | 88.10 ± 3.60 | 82.22 ± 2.50** | |
| 5 Gy | 60.00 ± 1.63 | 59.61 ± 1.73 | 50.30 ± 4.49** | |
| 10 Gy | 38.90 ± 3.16 | 38.40 ± 4.53 | 32.35 ± 2.49** | |
| SK-N-DZ | 0 Gy | 100 ± 7.42 | 100 ± 9.29 | 100 ± 1.86 |
| 2 Gy | 78.68 ± 2.70 | 77.00 ± 3.18 | 74.55 ± 3.18 | |
| 5 Gy | 52.13 ± 2.46 | 51.35 ± 2.47 | 46.89 ± 1.64** | |
| 10 Gy | 31.14 ± 2.78 | 29.01 ± 3.53 | 25.03 ± 2.05** | |
Table of cell viabilities (expressed as % of non-irradiated treatment control for a given concentration of nanoconjugates, after adjustment for baseline cytotoxicity) for SK-N-AS and SK-N-DZ cells treated with varying concentrations of bare nanocomposites and different doses of ionizing radiation (Fig. 5). Entries contain mean ± SD. **: < 0.01 significance level, *** < 0.001 significance level.
Cell viabilities in the presence of DOPAC–Fe3O4@TiO2 nanoconjugates following irradiation
| DOPAC–Fe3O4@TiO2 | 0 nM | 100 nM | 250 nM | |
| SK-N-AS | 0 Gy | 100 ± 5.06 | 100 ± 4.50 | 100 ± 10.11 |
| 2 Gy | 91.84 ± 5.50 | 57.60 ± 7.28*** | 53.50 ± 6.60*** | |
| 5 Gy | 59.38 ± 4.79 | 26.40 ± 5.56*** | 17.94 ± 4.54*** | |
| 10 Gy | 38.11 ± 2.35 | 14.53 ± 3.50*** | 7.58 ± 5.67*** | |
| SK-N-DZ | 0 Gy | 100 ± 10.12 | 100 ± 9.28 | 100 ± 17.87 |
| 2 Gy | 51.97 ± 4.34 | 40.35 ± 10.15* | 36.83 ± 17.71 | |
| 5 Gy | 40.06 ± 3.35 | 27.55 ± 3.86*** | 20.78 ± 12.76** | |
| 10 Gy | 17.52 ± 3.23 | 8.25 ± 3.84** | 5.20 ± 10.43* | |
Table of cell viabilities (expressed as % of non-irradiated treatment control for a given concentration of nanoconjugates, after adjustment for baseline cytotoxicity) for SK-N-AS and SK-N-DZ cells treated with varying concentrations of DOPAC-nanocomposites combined with varying doses of ionizing radiation, from Fig. 5. Entries contain mean ± SD. *: < 0.05 significance level, **: < 0.01 significance level, *** < 0.001 significance level